Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 10.00 RMB [6]. Core Views - The company reported a revenue of 8.21 billion RMB in 2025, a year-on-year decrease of 7.23%, and a net profit attributable to shareholders of 118 million RMB, down 3.85% year-on-year. However, the non-recurring net profit increased by 78.41% to 212 million RMB [1]. - Despite short-term profit pressures, the long-term recovery trend remains intact, driven by product structure optimization and potential growth in domestic demand policies [1][2]. - The company experienced a significant decline in overseas sales, with a 48.83% drop to 825 million RMB, primarily due to increased tariffs in the U.S. Domestic sales grew modestly by 2.04% to 7.39 billion RMB [2]. Summary by Sections Financial Performance - The company's gross margin improved to 26.77%, up 1.27 percentage points year-on-year, attributed to product structure optimization. The sales expense ratio was 16.95%, a slight decrease of 0.07 percentage points [3]. - The company faced fair value losses of 123 million RMB and foreign exchange losses, impacting overall profit performance [3]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026 and 2027 is adjusted to 307 million RMB and 376 million RMB, respectively, with an expected EPS of 0.40 RMB for 2026 [4]. - The company is valued at a PE ratio of 25 times for 2026, maintaining a target price of 10 RMB [4].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company's revenue for 2H25 reached 2.97 billion RMB, a year-on-year increase of 9.3%, surpassing the Visible Alpha consensus estimate of 2.94 billion RMB, primarily driven by rapid growth in corporate health management business due to group synergy [1] - Non-IFRS net profit was 250 million RMB, exceeding the consensus estimate of 160 million RMB, with a corresponding non-IFRS net profit margin of 8.4%, up 5.9 percentage points year-on-year, attributed to the increased proportion of high-margin corporate health management business, AI-enabled cost reduction and efficiency improvement, enhanced supply chain procurement capabilities, and some non-operating income [1] - The company is expected to benefit from deeper business collaboration post-consolidation with the group, opportunities in the commercial insurance sector, and ongoing AI technology implementation to enhance cost efficiency [1] Business Performance - The corporate health management revenue grew by 40.6% year-on-year to 1.31 billion RMB, driven by a steady increase in the number of partner enterprises [2] - The company reported a total of approximately 35 million paying users in 2025, an increase of 11.4%, achieving a penetration rate of 14% among the 250 million individual financial users of the Ping An Group [2] - The number of paying service enterprises reached 6,700, reflecting an increase of 83.1%, indicating robust customer acquisition progress [2] AI Development - The company has made significant progress in AI applications in healthcare, with AI contributing nearly 80 million RMB in gross profit, accounting for 4.5% of total gross profit [3] - The cost per consultation decreased by approximately 45% year-on-year in Q4 2025, thanks to the development of a comprehensive AI diagnosis and treatment system [3] - The management plans to increase investment in AI applications, transitioning from simple automation to deep assistance in various medical scenarios [3] Profit Forecast and Valuation - The non-IFRS net profit forecasts for 2026 and 2027 have been adjusted upward by 8.0% and 10.8% to 480 million RMB and 610 million RMB, respectively, due to the increasing share of platform business model and ongoing AI technology applications [4] - The valuation method has shifted from PS to EV/adjusted net profit, assigning a target EV/adjusted net profit multiple of 40x for 2026, reflecting a premium over the average of comparable companies [4] - The target price is set at 15.9 HKD per share, down from a previous estimate of 17.2 HKD, based on the new valuation approach [4]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 7.40, reflecting a price-to-sales (PS) ratio of 1.5x for 2026 [7][12]. Core Insights - The company reported total revenue of RMB 820 million for 2H25, a year-on-year decline of 20.7%, while the non-IFRS net profit was RMB 15 million, with a non-IFRS net profit margin of 1.8%, improving by 31.8 percentage points year-on-year. This decline in revenue is attributed to the company's strategic reduction of low-margin hardware business to enhance revenue quality and improve supply chain efficiency [1][2]. - Management anticipates over 20% revenue growth in 2026 while maintaining stable operating profit margins, focusing on advancements in AI ecosystem development, user growth trends, and cost reduction efficiencies [1][2]. Revenue and Profitability - The company's revenue for 2H25 was RMB 820 million, with proprietary brand sports product revenue declining by 15.7% to RMB 380 million, achieving a gross margin of 36.8%, up by 4.9 percentage points. The online membership and paid content revenue fell by 28.8% to RMB 340 million, with a gross margin of 70.7%, up by 9.6 percentage points [2][4]. - The overall gross margin for 2H25 was 52.1%, an increase of 4.6 percentage points year-on-year [2]. User Engagement and AI Integration - The average monthly active users decreased by 27.2% to 21.77 million, while the average revenue per user increased by RMB 0.5 to RMB 6.3. The average monthly subscription members were 2.74 million, with a membership penetration rate of 12.6% [3]. - The company has transitioned to an AI-driven sports health ecosystem, with plans to release AI products in 1H26. The AI capabilities have shown promising retention effects, with a next-day retention rate of 69% for AI data analysis features [4][5]. Financial Forecasts and Valuation Adjustments - The revenue forecasts for 2026 and 2027 have been adjusted downwards by 5.8% and 3.8% to RMB 19.9 billion and RMB 22.6 billion, respectively. The non-IFRS net profit forecasts for 2026 and 2027 have been reduced by 66.0% and 51.9% to RMB 30 million and RMB 80 million, respectively [12][13]. - The gross margin forecasts for 2026 and 2027 have been adjusted to 52.6% and 53.7%, respectively, reflecting the anticipated growth in lower-margin proprietary sports products [12][13].

Investment Rating - The investment rating for the company is maintained as "Hold" for A-shares and "Buy" for H-shares [7]. Core Views - The company's 2025 revenue reached 9.264 billion RMB, a year-on-year increase of 0.20%, while the net profit attributable to shareholders was 1.149 billion RMB, up 0.38% year-on-year. However, the company recorded a one-time impairment loss of 653 million RMB, impacting net profit by 587 million RMB, leading to results below expectations by 617 million RMB [1][2]. - The company plans to distribute a dividend of 0.244 RMB per share for the 2025 fiscal year, with a payout ratio of approximately 58.85%, resulting in dividend yields of 2.7% for A-shares and 3.7% for H-shares [1][5]. Revenue and Profitability - The toll revenue for 2025 increased by 1.4% year-on-year, and after excluding the impact of the exit of Yichang Expressway in March 2024, the adjusted toll revenue grew by 3.15% due to the opening of Jiangsu Phase II and favorable weather conditions [2]. - The gross margin for the highway business decreased by 5.2% year-on-year, primarily due to increased amortization and maintenance costs [2]. - The clean energy generation business remained stable, with revenue and gross profit showing a slight decline of 0.9% and an increase of 2.2%, respectively [3]. Capital Expenditure and Financial Health - The company raised 4.7 billion RMB through a private placement in 2025, reducing the debt-to-asset ratio from 59.7% at the beginning of the year to 55.0% by year-end [4]. - The capital expenditure plan for 2026-2028 is projected to reach 18.1 billion RMB, primarily directed towards new and expanded road projects and waste treatment initiatives [4]. Earnings Forecast and Valuation - The net profit forecasts for 2026 and 2027 have been revised down by 4.6% and 6.0% to 1.78 billion RMB and 1.58 billion RMB, respectively, with an initial forecast for 2028 set at 1.5 billion RMB [5]. - The target prices for A-shares and H-shares are set at 10.20 RMB and 8.50 HKD, respectively, reflecting a decrease from previous estimates [5][13].

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of RMB 9.80 [7]. Core Views - The company reported a total revenue of RMB 24.06 billion for 2025, representing a year-over-year increase of 27.96%, while the net profit attributable to shareholders was RMB 1.04 billion, down 19.91% year-over-year [2]. - The decline in net profit was attributed to weak lead and zinc prices and asset impairment, but the company retains core advantages in resource endowment, integrated mining and metallurgy layout, and high dividend attributes [2]. - Future highlights include resource replenishment, release of precious metal production capacity, and extension of high value-added industrial chains [2]. Summary by Sections Financial Performance - In Q4 2025, the company achieved revenue of RMB 6.88 billion, a year-over-year increase of 65.79% and a quarter-over-quarter increase of 4.31%, but reported a net loss of RMB 288 million, down 59.22% year-over-year and down 173.68% quarter-over-quarter [2]. - The annual gross margin was 15.82%, a decrease of 1.88 percentage points year-over-year, primarily due to weak lead and zinc prices and fluctuations in raw material costs [2]. - The total asset impairment loss for 2025 was RMB 203 million, impacting the net profit attributable to shareholders by RMB 133 million [2]. Production and Capacity - As of the end of 2025, the company had a refined lead and zinc production capacity of 420,000 tons per year and smelting capacity of 630,000 tons per year, with precious metals capacity exceeding 1,000 tons per year [3]. - The company is expected to increase silver ingot production by 380 tons per year and gold ingot production by 230 kilograms per year from new projects [3]. Resource and Dividend Policy - The company maintains a resource self-sufficiency rate of approximately 54%, with proven lead and zinc resources exceeding 32 million tons [4]. - The company plans to distribute a dividend of RMB 0.10 per share for 2025, which represents 74.54% of the net profit attributable to shareholders, highlighting its commitment to shareholder returns [4]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026-2028 is adjusted to RMB 2.45 billion, RMB 2.87 billion, and RMB 3.06 billion, respectively, with a three-year compound growth rate of 43.57% [5]. - The report assigns a price-to-earnings ratio of 20 times for 2026, leading to a target price of RMB 9.80, reflecting a cautious approach due to recent valuation increases in comparable companies [5].

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of RMB 9.80 [7]. Core Insights - The company reported a revenue of RMB 24.059 billion for 2025, representing a year-over-year increase of 27.96%, while the net profit attributable to shareholders was RMB 1.035 billion, down 19.91% year-over-year [2]. - The decline in net profit was attributed to weak lead and zinc prices and asset impairment, but the company retains core advantages in resource endowment, integrated mining and metallurgy layout, and high dividend attributes [2]. - Key future growth drivers include resource replenishment, release of precious metal production capacity, and extension of high value-added industrial chains [2]. Summary by Sections Financial Performance - In 2025, the company produced 694,700 tons of refined lead and zinc products, a year-over-year increase of 6.66%, and 233,400 tons of zinc alloys, up 20.62% [2]. - The gross profit margin for the year was 15.82%, a decrease of 1.88 percentage points year-over-year, primarily due to weak lead and zinc prices and fluctuations in raw material costs [2]. - The total asset impairment loss for 2025 was RMB 203 million, impacting the net profit attributable to shareholders by RMB 133 million [2]. Production Capacity and Growth - As of the end of 2025, the company had a lead and zinc concentrate production capacity of 420,000 tons per year and a smelting capacity of 630,000 tons per year, with precious metals capacity exceeding 1,000 tons per year [3]. - The company has initiated several projects to enhance production capacity, including the Hohhot Chihong precious metals comprehensive recovery project, which is expected to add 380 tons of silver ingots and 230 kilograms of gold ingots annually [3]. Resource Self-Sufficiency and Dividends - The company's resource self-sufficiency rate was approximately 54% in 2025, with proven lead and zinc resources exceeding 32 million tons [4]. - The company plans to distribute a dividend of RMB 0.10 per share for the 2025 fiscal year, which represents 74.54% of the net profit attributable to shareholders, highlighting its commitment to shareholder returns [4]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026-2028 is adjusted to RMB 2.451 billion, RMB 2.872 billion, and RMB 3.064 billion, respectively, with a compound annual growth rate of 43.57% [5]. - The report assigns a price-to-earnings ratio of 20 times for 2026, leading to a target price of RMB 9.80, reflecting a cautious approach given recent valuation increases in comparable companies [5].

Investment Rating - The investment rating for the company is maintained as "Hold" for A-shares and "Buy" for H-shares [7]. Core Views - The company's 2025 revenue reached 9.264 billion RMB, a year-on-year increase of 0.20%, while the net profit attributable to shareholders was 1.149 billion RMB, up 0.38% year-on-year. However, the company recorded a one-time impairment loss of 653 million RMB, impacting net profit by 587 million RMB, leading to results below expectations by 617 million RMB [1][2]. - The company plans to distribute a dividend of 0.244 RMB per share for the 2025 fiscal year, with a payout ratio of approximately 58.85%, resulting in dividend yields of 2.7% for A-shares and 3.7% for H-shares [1][5]. Summary by Sections Revenue and Profitability - The company's toll revenue increased by 1.4% year-on-year, and after excluding the impact of the exit of Yichang Expressway, the adjusted toll revenue grew by 3.15%. This growth was attributed to the opening of the Jiangsu section and favorable weather conditions [2]. - The gross margin for the highway business decreased by 5.2%, primarily due to increased amortization and maintenance costs. The clean energy generation business remained stable, while the solid waste resource recovery business showed a slight turnaround [1][3]. Environmental Business - In the environmental sector, the clean energy generation revenue and gross profit decreased by 0.9% and increased by 2.2%, respectively. The kitchen waste treatment revenue and gross profit grew by 20% and turned profitable, mainly due to the commercial operation of the Guangming Environmental Park and rising oil prices [3]. - The subsidiary, Lande Environmental, reduced its losses to 196 million RMB in 2025 from 397 million RMB in 2024, indicating a near break-even point [3]. Capital Expenditure and Financial Health - The company raised 4.7 billion RMB through a private placement in 2025, reducing its debt-to-asset ratio from 59.7% at the beginning of the year to 55.0% by year-end. However, the company has significant capital expenditure plans of 18.1 billion RMB from 2026 to 2028, which may lead to a slight increase in the debt-to-asset ratio to 56.5% by the end of 2028 [4][5]. Profit Forecast and Valuation - The net profit forecasts for 2026 and 2027 have been revised down by 4.6% and 6.0% to 1.78 billion RMB and 1.58 billion RMB, respectively. The 2028 net profit forecast is introduced at 1.5 billion RMB. The target prices for A-shares and H-shares are set at 10.2 RMB and 8.5 HKD, respectively [5][7].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 4.56 [6][4]. Core Insights - The company reported a revenue of RMB 18.11 billion and a net profit attributable to the parent of RMB 1.94 billion for the year 2025, representing a year-on-year decline of 12.7% and 45.7% respectively. The performance was below expectations, as the prior forecast anticipated a revenue decline of only 4.0% and a net profit decline of 14.8% [1]. - The company is currently undergoing a channel inventory clearance, which has led to a temporary decline in revenue. However, it is expected that operations will return to normal after the inventory is cleared, with positive impacts anticipated from fertility subsidies [1][2]. - The gross margin for 2025 decreased by 1.3 percentage points to 65.0%, while the net profit margin fell by 6.5 percentage points to 10.7%. The decline in profitability was primarily due to reduced government subsidies and losses from inventory devaluation [3]. Revenue and Profitability - The revenue from the dairy products and nutrition segment decreased by 12.6% year-on-year to RMB 18.00 billion, while the raw milk business saw a decline of 27.3% to RMB 1.1 billion. The second half of 2025 also reflected a similar trend with a 15.9% and 9.7% decline respectively [2]. - The company’s gross margin for infant formula increased by 2.2 percentage points to 73.5% in 2025, but overall gross margin was impacted by a higher proportion of lower-margin products sold [3]. Forecast and Valuation - The revenue forecast for 2026 and 2027 has been adjusted downwards to RMB 18.84 billion and RMB 19.51 billion, reflecting a decrease of 11% and 12% from previous estimates. The expected net profit for these years is RMB 2.77 billion and RMB 3.01 billion, which is a reduction of 24% and 27% respectively [4]. - The estimated earnings per share (EPS) for 2026, 2027, and 2028 are projected to be RMB 0.31, RMB 0.33, and RMB 0.35 respectively, with a price-to-earnings (PE) ratio of 13x applied to the 2026 earnings to derive the target price [4][10].

Investment Rating - The investment rating for Harbin Electric is maintained as "Buy" with a target price of HKD 29.15 [6][9]. Core Views - Harbin Electric reported a comprehensive improvement in revenue, profit, and orders for 2025, achieving a revenue of RMB 46.1 billion, a year-on-year increase of 19%, and a net profit attributable to the parent company of RMB 2.67 billion, up 58% year-on-year [7][9]. - The company is expected to benefit from the growth in domestic electricity demand and the increasing importance of traditional power supply, including coal, gas, water, and nuclear energy [7][9]. - The global shortage of electricity is creating opportunities for the company's gas turbine exports, with a significant increase in global gas turbine orders projected for 2025 [8][9]. Financial Performance - Revenue projections for the upcoming years are as follows: RMB 52.3 billion in 2026, RMB 57.3 billion in 2027, and RMB 59.8 billion in 2028, reflecting growth rates of 13.54%, 9.57%, and 4.39% respectively [5][9]. - The net profit attributable to the parent company is forecasted to reach RMB 3.54 billion in 2026, RMB 4.15 billion in 2027, and RMB 4.36 billion in 2028, with year-on-year growth rates of 32.72%, 17.21%, and 5.08% respectively [5][9]. - The earnings per share (EPS) are projected to be RMB 1.58 in 2026, RMB 1.85 in 2027, and RMB 1.95 in 2028 [5][9]. Order Growth and Market Opportunities - The company secured new orders worth RMB 64.6 billion in 2025, a year-on-year increase of 14%, with significant contributions from coal, hydro, and nuclear power sectors [7][9]. - The company is positioned to capitalize on the increasing electrification rates in regions like North America and the Middle East, which may lead to substantial export opportunities for its small gas turbines [8][9]. - The ongoing investment in energy infrastructure, with an expected increase of 40% in fixed asset investments during the 14th Five-Year Plan, supports the demand for traditional power supply equipment [7][9].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 47.00 and HKD 42.00 [6][5]. Core Insights - The company reported a net profit of RMB 53.5 billion for 2025, representing a year-on-year growth of 19%, driven by strong investment performance with a total investment return rate of 5.7%, an improvement of 0.1 percentage points year-on-year [1]. - The new business value (NBV) for life insurance grew by 40% year-on-year, indicating robust growth, with new single premiums increasing by 17.6% [2]. - The combined ratio (COR) for property insurance improved to 97.5%, a year-on-year improvement of 1.1 percentage points, reflecting steady underwriting performance [3]. - The net investment yield for 2025 was 3.4%, a decrease of 0.4 percentage points, while the total investment return rate increased by 0.1 percentage points [4]. - The company expects a 30% growth in life insurance NBV for 2026, supported by strong growth in the liability side during the low-interest-rate period [2]. Summary by Sections Life Insurance - The NBV for life insurance increased by 40% year-on-year, with a profit margin based on new single premiums rising to 19.8%, up 3.2 percentage points [2]. - The agent channel's NBV grew by 11.7%, while the bank insurance channel's NBV doubled, reflecting increased focus and investment in this area [2]. Property Insurance - Property insurance premiums remained stable, with a 3% increase in auto insurance premiums and a 3.1% decrease in non-auto insurance premiums [3]. - The COR for auto insurance improved to 95.6%, while the non-auto insurance COR was 99.9%, primarily affected by disruptions in guarantee insurance business [3]. Investment Performance - The company achieved a strong investment performance in 2025, with a total investment return rate of 5.7%, driven by increased equity positions and favorable capital market conditions [4]. - The company's net assets grew to RMB 302.1 billion, a year-on-year increase of 3.7% [4]. Profit Forecast and Valuation - The EPS forecast for 2026, 2027, and 2028 has been adjusted to RMB 5.26, RMB 5.46, and RMB 5.79, respectively, reflecting a downward adjustment of 7% and 12% for the first two years [5]. - The target price remains unchanged based on DCF valuation methods, maintaining a "Buy" rating [5].